News | March 13, 2021
AstraZeneca Pharma India receives approval for supplying Osimertinib in India
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The company will review FDA's response and decide on appropriate next steps soon.
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
The partnership is a significant step in delivering advanced cancer therapies to patients.
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Subscribe To Our Newsletter & Stay Updated
